Making informed decisions to change lives for the better
[image placeholder – do not delete]
At Sumitovant, we believe that the only way to develop therapies that have the potential to improve patient outcomes is to improve the drug candidate selection and drug development process.
Curiosity, inquisitiveness and an innate spirit of thinking differently about the challenges to effective drug development are at the core of who we are and what we do. And patients are the reason why we do it. Combined with a passionate team that strives to improve patient outcomes, we are also leveraging our unparalleled DrugOME™ technology and Digital Innovation™ platform to ask and answer critical questions that reduce development timelines and costs, reduce uncertainty and enable us to build and advance a diverse portfolio of transformative therapies across many indications, including cancer, reproductive health, pulmonary and urologic diseases and rare and ultra-rare disorders.
- Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies
- Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Unparalleled tech powers our unique approach to innovation
Cancer. Reproductive health. Pulmonary diseases. Urologic diseases. Rare and ultra-rare disorders. Our diverse pipeline candidates have one thing in common – significant unmet patient need. Meeting this need requires balance between tremendous scale and detailed understanding of specific disease indications, drug classes and clinical practices. We achieve this balance through our technology-enabled approach to drug discovery, development and commercialization, always keeping patient need at the center of what we do. The members of our leadership team have proven track records of success in developing and commercializing transformative therapies and, under their guidance, we believe we are positioned to pursue an improved process to improved therapies.
Myovant Sciences is committed to addressing unmet need in women’s health and advanced prostate cancer through purpose-driven science, empowering medicines, and transformative advocacy.
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
Enzyvant Therapeutics is focused on transformative therapies for rare, often fatal, diseases.
Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH).
Spirovant Sciences is focused on changing the course of cystic fibrosis and other pulmonary diseases.
The members of our leadership teams have industry-leading expertise in all aspects of drug discovery, development and commercialization, biopharmaceutical company operations, and the development and implementation of cutting-edge data acquisition, structure and analytical tools. But we bring more to Sumitovant than our professional success. We also bring or experiences as patients and as the physicians, family and friends who care for patients facing significant health challenges. We have witnessed both the benefits and limitations of biopharmaceutical science from multiple perspectives and have a singular focus on ensuring that everyone at Sumitovant has the resources and commitment to achieve our goals and milestones.